Development and characterization of a monoclonal antibody with cross-reactivity towards uracil and thymine, and its potential use in screening patients treated with 5-fluorouracil for possible risks

Clinica Chimica Acta

Volumn 322, Issue 1-2, 2002, Pages 59-66

  Honda, Teruko ^a,b,c   Inagawa, Hiroyuki ^a   Fukushima, Masakazu ^d   Moriyama, Akira ^d   Soma, Gen Ichiro ^a  

^a TOKUSHIMA BUNRI UNIVERSITY   (Japan)

^b NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^c KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^d TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

5 Fluorouracil; Diagnosis; Dihydropyrimidine dehydrogenase; Monoclonal antibody; Pyrimidine; Uracil

Indexed keywords

5 BROMO 1 CARBOXYMETHYLURACIL; CROSS REACTING ANTIBODY; CYTOSINE; DIHYDROPYRIMIDINE DEHYDROGENASE; DIHYDROURACIL; FLUOROURACIL; HAPTEN; MONOCLONAL ANTIBODY; N CARBAMYL BETA ALANINE; PSEUDOURIDINE; THYMINE; THYMINE DERIVATIVE; UNCLASSIFIED DRUG; URACIL; URACIL DERIVATIVE; URIDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY ISOLATION; ANTIBODY PRODUCTION; ANTIBODY SCREENING; ANTIBODY SPECIFICITY; ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG CONFORMATION; DRUG CROSS REACTIVITY; DRUG DETERMINATION; DRUG SAFETY; ENZYME DEFICIENCY; HUMAN; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RISK; SCREENING TEST;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CROSS REACTIONS; DIHYDROURACIL DEHYDROGENASE (NADP); ENZYME INHIBITORS; FLUOROURACIL; HUMANS; HYBRIDOMAS; MICE; MICE, INBRED BALB C; OXIDOREDUCTASES; PYRIMIDINES; RISK FACTORS; THYMINE; URACIL;

EID: 0036292103     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(02)00132-8     Document Type: Article

References (26)

1. Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy
2. Characterization of dihydropyrimidine dehydrogenase on immunohistochemistry in colon carcinoma, and correlation between immunohistochemical score and protein concentration or messenger RNA expression
3. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: Population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy
4. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity
5. Potential importance of dihydropyrimidine dehydrogenase (DPD) in cancer chemotherapy
6. Pharmacogenetics and cancer chemotherapy
7. Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer
8. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls
9. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: Frequency of the common IVS14+1G>A mutation causing DPD deficiency
10. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: Identification of new mutations in the DPD gene
11. Degradation of pyrimidines and pyrimidine analogs-pathways and mutual influences
12. Comparative study of thymine and uracil metabolism in healthy persons and in a patient with dihydropyrimidine dehydrogenase deficiency
13. New defects of pyrimidine metabolism
14. Possible prediction of adverse reactions to 5FU by an oral administration test
15. Automated screening system for purine and pyrimidine metabolism disorders using high-performance liquid chromatography
16. Monoclonal antibody to pseudouridine used to develop a radioimmunoassay
17. Quantitation of urinary nucleosides by high-performance liquid chromatography
18. Urinary screening for pyrimidine metabolism disorders. Reference ranges for dihydrouracil, uracil, and dihydrouracil/uracil ratio
19. Possible prediction of adverse reactions to fluorouracil by the measurement of urinary dihydrothymine and thymine
20. Dihydropyrimidine dehydrogenase deficiency leading to thymine-uraciluria. An inborn error of pyrimidine metabolism
21. 2-dimethylguanosine, 1-methylinosine, and pseudouridine
22. Urinary screening for pyrimidine metabolism disorders: Possible prediction of adverse reactions to pyrimidine chemotherapy
23. Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients